Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Nam H. Dang, Michinori Ogura, Sylvie Castaigne, Luis E. Fayad, Mats Jerkeman, John Radford, Antonio Pezzutto, Igor Bondarenko, Douglas A. Stewart, Michael Shnaidman, Sharon Sullivan, Erik Vandendries, Kensei Tobinai, Radhakrishnan Ramchandren, Paul A. Hamlin, Eva Giné, Kiyoshi Ando

Research output: Contribution to journal › Letter › peer-review

44 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.